The two-year question patients need answered first

Both microfracture and ChondroFiller injection can produce real, measurable improvement in the first year. Pain reduces, function improves, and on that basis the two approaches can look roughly equivalent to a patient weighing their options before treatment. That early similarity is the source of a common and consequential misreading.

The problem is that early improvement reflects initial defect coverage — the joint being quietened and the lesion being filled. It does not tell you what the repair tissue is made of, how it behaves under years of normal load, or what happens to the bone immediately beneath it. Those factors, shaped by biology rather than surgical skill, are what determine whether improvement persists or reverses. For patients with focal cartilage lesions — typically ICRS grade III or IV — that reversal, when it happens, tends to become clinically apparent somewhere between two and three years post-treatment.

For anyone making a cartilage repair decision now, the two-to-three-year window is the one that matters most. Choosing based on early outcomes alone is choosing based on the part of the evidence that flatters both options equally.

What microfracture does and why it shows early results

Microfracture works by making small perforations through the subchondral bone plate — the dense bone immediately beneath the damaged cartilage surface. This releases marrow-derived mesenchymal stem cells into the defect, where they form a blood clot that matures into repair tissue over the following months.

That repair tissue is fibrocartilage. Native articular cartilage is built primarily from Type II collagen, which gives it the compressive stiffness and fatigue resistance to tolerate decades of cyclic joint loading. Fibrocartilage is dominated by Type I collagen — structurally closer to scar tissue — and is softer and less suited to sustained mechanical stress.

In the short term, fibrocartilage does fill the defect, and that filling is enough to reduce pain and improve function in the first twelve to eighteen months. Outcome scores rose measurably in early cohorts, which is why the technique was widely adopted and why the initial optimism was not misplaced. The limitation is structural, not procedural: the tissue that produces those early gains lacks the architecture to maintain them under normal load over time.

Microfracture was historically applied to smaller focal defects — typically under 2 cm² — where the expectation of reasonable short-term relief was well founded. Its current decline reflects the medium- and long-term evidence that has accumulated since, not a reassessment of its early-stage logic.

Why microfracture breaks down between years two and three

The structural limitations described in the previous section would be manageable if the repair tissue simply wore out gradually. What makes microfracture outcomes deteriorate more sharply is a secondary process occurring in the bone beneath the defect — one that begins well before symptom return becomes apparent.

By breaching the subchondral plate, microfracture can trigger a secondary centre of ossification. This manifests as intralesional osteophyte formation — abnormal bone growth within the repair zone — documented in 54% of patients at six months and approximately 70% at twelve months post-procedure. Subchondral bone cysts develop concurrently in up to 33% of cases. Both findings are captured in the 2022 early osteoarthritis literature, with the mechanistic relationship between subchondral remodelling and cartilage resurfacing quality characterised by Chen et al. (American Journal of Sports Medicine, 2011).

The clinical significance lies in the timing. Osteophyte growth peaks by twelve months — meaning the bone changes underneath the repair surface are already advancing before most patients notice any deterioration. When load demand increases as activity returns to normal levels, that compromised subchondral foundation accelerates surface breakdown rather than distributing stress across it. The result is symptom recurrence and progressive structural loss, typically becoming clinically evident between years two and three.

There is a further, practical consequence. Subchondral bone damage from microfracture complicates any subsequent cartilage repair procedure: altered bone architecture in the defect bed narrows the options available at revision. Published evidence suggests that higher failure rates follow cartilage restoration attempts in joints where prior marrow stimulation has already disrupted the subchondral unit — a consideration that is relevant well before a first-line treatment decision is made.

How ChondroFiller injection avoids the same failure path

Delivered as an ultrasound-guided outpatient injection, ChondroFiller works without making any contact with the subchondral bone plate. The scaffold — an acellular, in-situ gelling gel of murine-derived Type I collagen — is placed directly into the cartilage defect under image guidance, leaving the dense bone layer beneath entirely intact.

That single structural fact breaks the chain of events described in the previous section. With the subchondral plate unbreached, there is no marrow exposure, no secondary centre of ossification, and therefore no mechanical basis for the intralesional osteophyte growth or cyst formation that progressively undermines microfracture repair tissue.

Once placed, the collagen matrix acts as a chemotactic scaffold: its architecture provides a three-dimensional structure that draws in the patient's own progenitor cells from the surrounding tissue. Those cells migrate into the gel and differentiate endogenously — a process termed matrix-induced chondrogenesis. No cells are extracted, cultured, or transplanted; the repair biology remains entirely the patient's own, guided by the scaffold's physical and biochemical environment rather than introduced from outside.

ChondroFiller is a CE-marked Class III medical device, with clinical applications documented across the knee, hip, ankle, shoulder, wrist, and thumb. The current outpatient injection pathway differs from the arthroscopic delivery route described in some earlier clinical literature — a distinction worth noting when reviewing evidence from different time periods or procedural settings.

What the clinical data show at two to three years

The Jerosch et al. prospective post-market clinical follow-up study provides the clearest evidence of that diverging trajectory. At three years, patients who received ChondroFiller injection recorded a mean IKDC score of 80 — a validated measure of knee function scaled to 100 — representing an improvement of 32.4 points from baseline. Crucially, that figure was sustained and marginally higher than scores recorded at earlier follow-up points. Microfracture, by contrast, typically peaks functionally in the first year before declining as subchondral changes accumulate; a score still rising at three years is a fundamentally different clinical story.

The structural picture supports the functional one. MOCART — an MRI-based measure of how completely a repair integrates with surrounding native cartilage — reached 81.6 to 84.3 across published ChondroFiller injection studies, indicating greater than 80% defect filling with good tissue continuity. Progression from a mean of 65.3 at four weeks to 81.6 at one year shows the collagen matrix continuing to mature through year one rather than plateauing, which is consistent with the biology of gradual progenitor-cell-driven remodelling. Across four knee studies, IKDC improvements exceeded the 16.7-point minimum clinically important difference — the threshold at which a patient reliably notices a change — confirming that the gains are meaningful rather than statistical noise. More than 20,000 implantations have been performed over a decade, with a reported complaint rate of approximately 0.06%.

The evidence carries three honest limitations. There is no published head-to-head randomised controlled trial directly comparing ChondroFiller injection with microfracture at pre-specified two-to-three-year endpoints. The studies that do exist are largely manufacturer-sponsored. And independent five-to-ten-year follow-up data remain outstanding. What a reasonable patient should take from this is that the results are consistent, mechanistically well-grounded, and clinically meaningful — but not yet verified at the scale or independence that would place them beyond reasonable scientific question. The data are encouraging, not conclusive.

Deciding between these options and getting assessed

Understanding the biology helps narrow the choice, but three practical variables determine which pathway fits any individual: defect size, subchondral bone integrity, and prior treatment history.

The comparison explored in this article is most directly relevant for patients with focal ICRS grade III–IV lesions — roughly up to 3 cm², extendable to 6 cm² for ChondroFiller injection — who are seeking active restoration rather than symptom management alone. Patients who had microfracture two to three years ago and are now noticing returning symptoms should know that subchondral changes may already have altered which repair options remain viable; that picture requires specialist MRI review before any decision is made.

This is also not a binary choice. Depending on defect size, age, and prior procedures, other pathways may be more appropriate: matrix-augmented microfracture (AMIC, which adds a scaffold over the marrow-stimulation site), cell-seeded collagen-membrane grafts (MACI), autologous osteochondral plug transfer (OATS), and fresh osteochondral allograft for larger or post-traumatic defects each serve different parts of the indication spectrum. The questions worth raising with any cartilage specialist are straightforward: what does the MRI show about subchondral integrity, what are the grade and dimensions of the defect, and has any previous procedure changed the local bone architecture?

Professor Paul Y. F. Lee and the London Cartilage Clinic team carry out that type of structured assessment; an initial consultation can be arranged at londoncartilage.com.